藥品新興市場：印尼及菲律賓 是由出版商Datamonitor在2009年10月所出版的。
這份英文市場調查報告書包含81 pages 價格從美金7600起跳。
藥品產業將矚目焦點從先進國家市場成熟化轉到未來可望長期發展的新興市場上。特別是菲律賓及印尼的醫療制度正進行大幅度的改革。
本報告書內容包括：藥品產業整體動向、印尼及菲律賓市場的成長因素、進入該市場的策略等。內容綱要摘記如下：
實施概要
印尼藥品市場
- 雖然有許多潛在患者，但國内製造據點的條件影響許多外國企業
- 印尼的人口統計動向
- 印尼的社會經濟環境摘要
- 印尼的醫療制度
- 醫療費雖便宜，但有增加的趨勢
- 醫療保險範圍未涵蓋全國國民
- 在2013年之前提高醫療收益並涵蓋全體國民的全民保險計畫正在規畫當中
- 印尼法規限制問題
- 智慧財產權保護情況不佳，偽藥是個大問題
- 透過藥劑及登記制度保護國内產業
- 印尼的藥價及補貼
- 持續降價促使非專利藥品發展，同時使其成為國際品牌製造商的威脅
- 藥劑標籤上必須記載價格及一般名稱
- 原料高漲使藥價上漲
- 補貼非常有限
- 藥品市場動向
- 印尼的大型製藥企業
- 國際製藥企業
- 國内主要企業分析
- 主要治療領域
- 主要藥品品牌
菲律賓藥品市場
- 政府壓低價格及促進利用非專利藥品的對策使大型製藥企業面臨更嚴峻的環境
- 菲律賓的人口統計動向
- 菲律賓的社會經濟環境摘要
- 菲律賓的醫療制度
- 極度細分化的醫療制度
- FOURmula One實施為了改善醫療制度不公平性及細分化情形的4大改革方案
- 菲律賓法規限制問題
- 菲律賓的藥價及補貼
- 藥價因自由價格制定法而逐漸轉為規範市場
- 補貼雖然有限，但政府預計擴大財務保護政策
- 藥品市場動向
- 品牌非專利藥品可望提高市場佔有率
- 菲律的大型製藥企業
- 國際製藥企業
- 國内主要企業分析
- 主要治療領域
- 主要藥品品牌
參考資料
表
圖
Abstract
Introduction
As the developed markets are becoming increasingly mature, Pharma is turning
to the emerging markets, where long-term growth can be sustained. Of
particular interest are Indonesia and the Philippines, which are currently
going through major reforms to expand their healthcare systems; however there
are key differences between these two markets.
Scope of this research
- Provides a comparative overview of recent events affecting the
macroeconomic and pharmaceutical landscape
- Examines different drivers and resistors for growth in Indonesia and the
Philippines
- Analyzes the growth drivers of multinational and domestic players
operating in these markets
- Identifies key strategies for entry and expansion in these markets
Research and analysis highlights
The global economic downturn has impacted Indonesia, albeit at a lesser extent
than developed countries. Indonesia' s economic prowess has resulted in the
country potentially joining the top tier of emerging markets including Brazil,
Russia, India and China in the near future, as these are to grow at a faster
rate than developed countries.
With the introduction of a single South East Asian market via the free trade
agreement Association of South East Asian Nations (ASEAN) from 2011, in
addition to a full universal insurance coverage in the Philippines and
Indonesia by 2010 and 2013, respectively, the opportunity of pharmaceutical
players to maximize sales will increase.
Domestic pharmaceutical companies in both Indonesia and the Philippines are
ideal M&A targets for multinationals looking to enter or expand in these
markets. This is due to their double digit sales growth, which will be further
fuelled by the growing demand for low cost medicine as healthcare coverage
expands.
Key reasons to purchase this research
- Understand how recent events and trends will affect the pharmaceutical
markets in Indonesia and the Philippines
- Gain insight into which companies are growing rapidly and what strategies
they have employed
- Identify the opportunities and barriers to entering pharma markets in
Indonesia and the Philippines
Table of Contents
EXECUTIVE SUMMARY
- Strategic scoping and focus
- Key Findings
- Socioeconomic comparison - Indonesia has a larger patient potential
but the Philippines is more attractive in the short-term due to greater
healthcare access
- Pharmaceutical market comparison - the larger market size, growth rate
and brand preference makes the Philippines an attractive market for
multinationals
- Regulatory comparison - both Indonesia and the Philippines have
difficult regulatory environments
2. THE PHARMACEUTICAL MARKET IN INDONESIA
- Despite a large patient potential, the requirement for a domestic
manufacturing hub impacts the many foreign players
- Demographic trends in Indonesia
- Summary of socioeconomic environment in Indonesia
- Political environment - the Democratic party fostered stability and
economic growth
- The healthcare system in Indonesia
- Healthcare expenditure in Indonesia is low, but set to increase
- Health insurance does not cover the whole population despite the
availability of several different schemes
- Universal health insurance aims to improve health outcomes and cover all
Indonesians by 2013
- Regulatory issues in Indonesia
- Protection of intellectual property rights are weak and counterfeit
drugs are a major problem
- Registration of drugs aims to protect the local industry
- Pricing and Reimbursement in Indonesia
- Continuous price cuts incentivize generics and pose a threat to
multinational branded pharma companies
- Drug labeling now required to include price and generic name
- Rising costs of raw materials has resulted in escalating drug prices
- Reimbursement is very limited
- Pharmaceutical market dynamics
- Top pharmaceutical companies in Indonesia
- Top international pharmaceutical companies
- Analysis of top domestic pharmaceutical companies
- Top therapeutic areas by sales value
- Top pharmaceutical brands
3. THE PHARMACEUTICAL MARKET IN THE PHILIPPINES
- Government-imposed price cuts and measures to boost generics are creating
a more challenging environment for Big Pharma
- Demographic trends in the Philippines
- Summary of socioeconomic environment in the Philippines
- Political environment - approaching stability but more disruption
anticipated in the short-term
- Gross domestic product (GDP) growth has been subject to a steep decline
from 2008
- The Healthcare system in the Philippines
- The Philippines' s healthcare system is highly fragmented
- FOURmula One combines four reforms to tackle inequities and
fragmentation in the healthcare system
- Regulatory issues in the Philippines
- Foreign firms fear pharmaceutical IP will weaken through the Cheaper
Medicines Bill
- A revamped regulatory body expands its powers to seize counterfeit drugs
- Pricing and Reimbursement in the Philippines
- Pricing: the Philippines has shifted from a free-pricing approach to an
increasingly regulated market
- Reimbursement is limited but the government is now looking to expand
financial protection
- Pharmaceutical market dynamics
- Branded generics are set to see an increase in market share
- Top pharmaceutical companies in the Philippines
- Top international pharmaceutical companies
- Analysis of top domestic companies
- Top therapeutic areas
- Top pharmaceutical brands
4. BIBLIOGRAPHY
- Publications and online articles
TABLES
- Table: Key comparators: Indonesia versus the Philippines
- Table: Demographic indicators for Indonesia, 2006
- Table: Top 10 causes of death in Indonesia, 2006
- Table: Key economic indicators for Indonesia, 2000 - 09
- Table: Health expenditure indicators for Indonesia:, 2006
- Table: Type and coverage of the current health insurance system in
Indonesia, 2009
- Table: Sales growth for the top 15 pharmaceutical companies in Indonesia
($ and %), 2008
- Table: Volume growth for the top 15 pharmaceutical companies in Indonesia
(IMS Standard Units and %), 2008
- Table: Kalbe Farma' s recent deals expand its presence in the value chain,
2006 - 09
- Table: Sales growth according to therapy area in Indonesia ($ and %), 2004
- 08
- Table: Volume growth according to therapy area in Indonesia ($ and %),,
2004 - 08
- Table: Sales growth for the top 15 pharmaceutical brands in Indonesia ($
and %), 2008
- Table: Volume growth for the top 15 pharmaceutical brands in Indonesia
(IMS Standard Units and %) , 2008
- Table: Demographic indicators for the Philippines, 2006
- Table: Top 10 causes of death in the Philippines, 2006
- Table: Key economic indicators for the Philippines, 2000 - 09
- Table: Health expenditure indicators in the Philippines, 2006
- Table: Sales growth for the top 15 pharmaceutical companies in the
Philippines ($ and %) , 2004 - 08
- Table: Volume growth for the top 15 pharmaceutical companies in the
Philippines (IMS Standard Units and %) , 2004 - 08
- Table: Sales growth according to therapy area in the Philippines ($ and
%), 2004 - 08
- Table: Volume growth according to therapy area in the Philippines IMS
Standard Units and $m), 2004 - 08
- Table: Sales growth for the top 15 pharmaceutical brands in the
Philippines ($ and %), 2004 - 08
- Table: Volume growth for the top 15 pharmaceutical brands in the
Philippines (IMS Standard Units and %), 2008
FIGURES
- Figure: Key macroeconomic factors and healthcare system characteristics in
Indonesia, 2009
- Figure: Pharmaceutical market dynamics in Indonesia, 2009
- Figure: Drivers and barriers for multinationals wishing to enter
Indonesia, 2009
- Figure: Indonesia' s transition to universal healthcare coverage, 2009
- Figure: Sales and volume of the Indonesian pharmaceutical market ($m and
IMS Standard Units), 2004 - 08
- Figure: Sales growth for the top 15 pharmaceutical companies in Indonesia
(%), 2004 - 08
- Figure: Pharmaceutical sales by therapy class in Indonesia (%), 2004 - 08
- Figure: Key macroeconomic factors and healthcare system characteristics in
the Philippines, 2009
- Figure: Pharmaceutical market dynamics in the Philippines, 2009
- Figure: Drivers and barriers for multinationals wishing to enter the
Philippines, 2009
- Figure: Structure of the Philippine healthcare system, 2009
- Figure: The Philippines Health Sector Reform Agenda (HRSA) consists of
five interrelated reform areas
- Figure: Reforms to lower prices of drugs have not lived up to expectations
in the Philippines
- Figure: Sales and volume of the pharmaceutical market in the Philippines,
2004 - 08
- Figure: Sales growth for the top 15 pharmaceutical companies in the
Philippines (%), 2008
- Figure: Pharmaceutical sales by therapy class in the Philippines (%), 2004
- 08
|
